Lots and lots of #lipids today @diabetespc this time with @PNewlandJones covering the fundamentals we all need to know for #PLWD

Once again standing room only!
And managed to catch his eye to say 😀 for the camera 📸 Phil explaining how lipids have become unnecessarily complicated

We have gone from one medicine and one back up to multiple options for lipid management

Today going to take things back to fundamentals

Catching @drsarahjdavies and @drnkan in the heart🫀and kidney clinic letting us know about reducing CV events

🧵 ⬇️ @UKCPADiabetes @UKCPACardiac @diabetespc #DPC22 CVD remains responsible for 24% of deaths in the UK

1 death every 3 minutes ⏱️

A 🧵for anyone prescribing, monitoring or seeing people on drug Tx for HF from @escardio #esc2022

"The practicalities of drug treatment in HF" 💔💊 with lots and lots of top tips⤵️

Great advice from conference that you can apply day to day! @GoggleDocs @UKCPACardiac @UKCPA ESC Guidelines for HFrEF treatment:

Look at the quality of that evidence and recommendations for drug Tx! 😃💊

Getting my #flozin fix on a Sunday catching up on #ESC2022 #ESCCongress2022 some thoughts in a thread 🧵 @UKCPACardiac @UKCPA @UKCPADiabetes
@escardio @hFRenDsUK

Let's start with the headline, drum roll please 🥁... Dapagliflozin in HFmrEF and HFpEF DELIVER Trial results 1. Background💔
HFpEF pts represent approx 50% of all people with HF
Currently limited Tx options in this group
Uncertainty remains re:
- People in highest part of EF range, ?attenuation of Tx effect
- People initiated on Tx during/soon after hospitalisation
- EF improved to >40%